Researchers conducted a clinical trial across 23 U.S. sites.
Six findings:
1. The M6-C artificial cervical disc was linked to reduced pain and opioid use compared to ACDF patients. The control group continued using opioids at seven times the rate of M6-C patients at 24 months.
2. The M6-C disc patients had an 86.8 percent overall success rate at 24 months, compared to 79.3 percent in the control group.
3. The average surgery time was 74.5 minutes for M6-C patients and 120.2 minutes for ACDF patients.
4. Subsequent surgery was necessary in 4.8 percent of ACDF patients and 1.9 percent of M6-C disc patients.
5. About 4 percent of patients in the M6-C group experienced serious adverse events related to the device or procedure, compared to about 6 percent in the ACDF group.
6. Cervical disc replacement with the M6-C disc is on-par with ACDF treatment, researchers concluded.
More articles on devices:
What drives orthopedic, spine device company M&A today and what to watch for through 2020
Medtronic requests review in $23M patent infringement decision
Stryker makes 2 legal leadership changes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
